What Luminate Medical does

Luminate Medical is a Galway, Ireland-based medical device and digital health company developing technologies to mitigate chemotherapy side effects and to enable home-based cancer care delivery. The company originated from research at the University of Galway in 2019 by founders Aaron Hannon, Dr. Bárbara Oliveira, and Prof. Martin O'Halloran, spun out in 2021, and is now backed by Artis Ventures, 8VC, and a syndicate that includes Y Combinator alumni networks and Atlantic Bridge, with cumulative disclosed venture funding of approximately $21 million plus over €13 million in Irish government DTIF grants.

The company's hardware portfolio centers on three devices: Lily, a wearable portable headset that uses a non-cooling compression approach to reduce chemotherapy-induced hair loss; Lilac, compression gloves and boots designed to prevent chemotherapy-induced peripheral neuropathy by reducing drug delivery to peripheral nerves; and the Lotus Infusion Set, which enables patients or caregivers to gain IV access via a previously implanted port without manual needle placement. These sit alongside the Lotus Home Infusion platform, a software-enabled nurse-led at-home chemotherapy administration service with real-time EMR integration, a patient-nurse video care component, and remote monitoring/scheduling functionality.

Luminate's business model rests on three revenue streams: managed home infusion services delivered under value-based care agreements with health plans (with cited economics of approximately $2,100 in savings per visit and 67% lower co-pays for high-cost oncology medications); prospective device sales post-FDA approval; and clinical trial services with pharmaceutical partners and academic medical centers (LOTUS-ONE, IMPACT, HORIZON). Go-to-market is enterprise B2B targeting oncology providers, health systems, health plans, and pharmaceutical companies, with a stated target to launch home infusion services across 40 partner clinics and an operational footprint spanning Ireland (Galway HQ and R&D) and the United States (New York regional operations for clinical trials and commercial rollout).

Name

Luminate Medical

Legal name

Luminate Medical

Website

https://luminatemed.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Medical Devices for Cancer Care

NAICS

Home Health Care Services (62161), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)

SIC

Services-Home Health Care Services (8082), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Virtual Nursing, Telemonitoring & Command Center Platforms (HLACAFAH)

akta.pro secondary industries

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Compression Therapy for Venous/Lymphedema (Bandages, Wraps, Garments) (HLAHALAF)

Keywords

• Medical devices oncology
• Home infusion services
• Chemotherapy side effects
• Compression therapy devices
• Cancer care delivery

Headquarters

HQ city

Galway

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Home Infusion Services: Lotus Home Infusion Program delivers cancer treatment at home through oncology-certified nurses. Revenue generated through value-based care agreements with health plans, reducing total cost of care. Providers maintain drug dispensing margins while Luminate manages home delivery and billing.
2. Medical Device Sales: Sale of proprietary medical devices including Lily (hair loss prevention), Lilac (neuropathy prevention), and Lotus Infusion Set. Devices are currently in clinical trials; commercial roll-out anticipated post-FDA approval.
3. Clinical Trial Services: Revenue from conducting clinical trials (LOTUS-ONE, IMPACT, HORIZON) in partnership with pharma companies and academic medical centers. Generates evidence for device efficacy and builds commercial relationships.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Luminate Medical develops wearable medical devices (Lily headset for hair loss prevention, Lilac compression gloves/boots for neuropathy prevention, Lotus Infusion Set for IV access) and operates the Lotus Home Infusion platform that delivers nurse-led cancer treatment at home in partnership with health systems. The company's core technology combines proprietary non-cooling compression therapy devices with a software platform for patient-nurse video care and EMR integration.

Product overview

Luminate Medical offers a suite of medical devices and software for at-home cancer treatment. The core platform is Lotus Home Infusion, a nurse-led at-home cancer care program delivering chemotherapy through health system partnerships. This platform integrates with device products including Lily (wearable headset for hair loss prevention), Lilac (compression gloves and boots for peripheral neuropathy prevention), and the Lotus Infusion Set (IV access device). An add-on software component called Lotus SC provides remote monitoring and self-administration capabilities. The portfolio is designed to reduce the need for clinic visits during chemotherapy treatment.

Differentiator

Problem solved

Functional benefit

Brands

• Lotus: Home infusion program enabling nurse-led at-home cancer treatment, partnering with health systems and practices.
• Lilac
• Lily
• Lotus Home Infusion
• Lotus Infusion Set
• Lotus SC

Quantifiable outcome

• Saves $2,100 per visit for high-cost oncology medications
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core, major and minor.

• University of GalwaycoreStrategic or Co-development Partner · 1 January 2019Origin of Luminate's technology through research by founders Aaron Hannon, Dr. Bárbara Oliveira, and Prof. Martin O'Halloran in medical device research.
• Multiple US Clinical SitesmajorStrategic or Co-development PartnerActively enrolling clinical sites for LOTUS-ONE, IMPACT, and HORIZON clinical trials across the United States for real-world evidence generation.
• Dexcom Executive (Board Appointment)minorOthersAppointed a Dexcom executive to the board in late 2024, bringing healthcare technology operational expertise.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Dignitana: Dignitana markets DigniCap, an FDA-cleared scalp-cooling system to prevent chemotherapy-induced hair loss. Directly comparable to Luminate's Lily device as the most established scalp-cooling player.
• Paxman: Paxman is the global leader in scalp cooling with the Orbis system used across thousands of oncology clinics. Direct competitor to Luminate's Lily hair-loss prevention device.
• Option Care Health: Option Care Health is the largest U.S. provider of home and alternate-site infusion services, including oncology. Directly comparable to Luminate's Lotus Home Infusion platform in care delivery model and customer base.
• Soleo Health: Soleo Health is a specialty home infusion provider focused on complex therapies including oncology. Comparable to Lotus Home Infusion in clinical model and payer value-based arrangements.

Emerging players

• Cooler Heads Care: Cooler Heads Care (Amma device) offers portable, patient-controlled scalp cooling for chemo patients. Emerging competitor in the same hair-loss prevention category as Luminate's Lily.
• Thyme Care: Thyme Care provides value-based oncology navigation and care coordination with health plans. Comparable to Luminate's payer-facing value-based care model for oncology cost reduction.

Broad incumbents

• BrightSpring Health Services: BrightSpring operates a broad home and community health services platform, including specialty/home infusion pharmacy. Comparable as an established operator Luminate is attempting to build against in oncology home infusion.
• OneOncology: OneOncology is a national platform partnering with community oncology practices to deliver value-based cancer care. Comparable as a broader incumbent serving the same oncology providers Luminate targets.
• McKesson (US Oncology Network): McKesson operates US Oncology Network and specialty distribution/home infusion for oncology. Comparable as a broad incumbent in oncology drug delivery, provider enablement, and home-based cancer services.

Others

• Flatiron Health: Flatiron Health (Roche) provides oncology-specific EHR, real-world evidence, and care-management tools used by oncology providers and pharma. Comparable as an oncology data and provider-enablement layer adjacent to Luminate's EMR-integrated platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/luminatemed

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds7 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luminate Medical